Aerie Pharmaceuticals Inc SMA 200
Mi az Aerie Pharmaceuticals Inc SMA 200?
A SMA 200 az Aerie Pharmaceuticals Inc - $15 +0.05%
Mi a SMA 200 meghatározása?
Az SMA 200 az utolsó 200 nap átlagos részvényárfolyama, amelyet az előző 200 záróár súlyozott átlagaként számítottak ki.
Simple moving average of 200 days for a stock is an unweighted moving average over the past 200 days. Moving averages will always exhibit a lag and the longer the period used for averaging the greater the lag will be. Because of the large amounts of data considered when calculating a long-term moving average, it takes a considerable amount of movement in the market to cause the moving average to change its course.
Using a moving average to confirm a trend in price is one of the most basic, yet effecting ways of using the indicator. Moving averages take into account what has already happened and a whole range of past events, which makes them such a good technical analysis tool for trend confirmations. Generally, a long-term moving average that is clearly on the upswing is a confirmation of a bullish trend. Conversely, a long-term moving average that is clearly on the downswing is a confirmation of a bearish trend.
SMA 200 a Health Care szektor a NASDAQ-on cégekben a Aerie Pharmaceuticals Inc -hoz képest
Mit csinál Aerie Pharmaceuticals Inc?
Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases. Aerie's first product, Rhopressa® (netarsudil ophthalmic solution) 0.02%, a once-daily eye drop approved by the U.S. Food and Drug Administration (FDA) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, was launched in the United States in April 2018. In clinical trials of Rhopressa®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. Aerie's second product for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension, Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%, the first and only fixed-dose combination of Rhopressa® and the widely-prescribed PGA (prostaglandin analog) latanoprost, was launched in the United States in May 2019. In clinical trials of Rocklatan®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. Aerie continues to focus on global expansion and the development of additional product candidates and technologies in ophthalmology, including for wet age-related macular degeneration and diabetic macular edema.
sma 200 -hoz hasonló cégek Aerie Pharmaceuticals Inc
- BlackRock Maryland Municipal Bond Trust nak SMA 200 $15 -1.47% van
- Neogen nak SMA 200 $15 +0.16% van
- ANGLE Plc nak SMA 200 GBX15 -38.37% van
- Lang + Schwarz Ag Na Konv nak SMA 200 €15 +15.34% van
- Elanco Animal Health Inc nak SMA 200 $15 -5.24% van
- LMP Capital and Income Fund Inc nak SMA 200 $15 +6.90% van
- Aerie Pharmaceuticals Inc nak SMA 200 $15 +0.05% van
- Prudential Bancorp Inc nak SMA 200 $15 -0.77% van
- Civista Bancshares Inc nak SMA 200 $15 +7.61% van
- Tirupati Sarjan nak SMA 200 ₨15 +20.91% van
- Caredx Inc nak SMA 200 $15 +46.50% van
- EasyETF - BNP Paribas Easy Euro Stoxx 50 UCITS ETF nak SMA 200 €15 +0.12% van
- Surteco SE nak SMA 200 €15 -1.82% van